TME Pharma N.V. announced that certain holders of the bonds issued in May and August, 2025 have agreed in principle to extend the maturity of the bonds for a one year period. These bond holders, Diede van den Ouden (CEO) and 2 members of the Supervisory Board, hold 29% of the regular bonds issued in May and August 2025 for a total face value amount of ?718,946. A successful extension of the entire May and August bonds would extend the Company?s financial visibility to more than twelve months, into in Second Quarter 2027.
Taking into account the current reduction in costs to approximately ?110k per month (where possible, costs will continue to be cut) and the cash position of around ?2.1M at November 14, 2025. Current financial visibility ends at May 28, 2026 with the existing bond maturity dates. Under the bond extensions under discussion, the main conditions of the loans would not change, except for the extension by one year bringing the new maturity date to May 28, 2027, and the increase in total loan reimbursement amount, which would have to be repaid at 104.7% of the nominal value of the bond in cash at the new maturity date (as compared to 93.5% of the bond nominal value at May 28, 2026) or at 112% of the nominal value of the bond in the case of conversion to shares (formerly 100% of the bond nominal value).
